Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2005

01-02-2005 | Review

Role of beta-lactam agents in the treatment of community-acquired pneumonia

Author: J. Garau

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2005

Login to get access

Abstract

Community-acquired pneumonia (CAP) is a common illness associated with high rates of morbidity and mortality worldwide. The β-lactam antibacterial agents have been the mainstay of therapy for CAP for over four decades and remain as first-line therapy. However, the impact of the substantial prevalence of resistance seen among the common respiratory pathogens, particularly penicillin and macrolide resistance among Streptococcus pneumoniae, is now an area for concern. CAP treatment guidelines often recommend the use of a macrolide or fluoroquinolone in conjunction with, or as an alternative to, β-lactam agents, but whether this is necessary is uncertain. This review outlines the historical use of β-lactam antibacterial agents in the treatment of CAP along with their ongoing therapeutic utility.
Literature
1.
World Health Organization (1999) WHO infectious disease report. http://​www.​who.​int/​infectious-diseases-report/​index.​htm.​ Cited 1 March 2004
2.
Meyer RD, Finch RG (1992) Community-acquired pneumonia. J Hosp Infect 22(Suppl A):51–59
3.
Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333:1618–1624CrossRef
4.
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) American Thoracic Society guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 163:1730–1754PubMed
5.
Medicare and Medicaid statistical supplement (1997) Health Care Fin Rev 18(Suppl):73
6.
Gil A, San-Martín M, Carrasco P, Gónzalez A (2002) Epidemiology of pneumonia hospitalizations in Spain, 1995–1998. J Infect 44:84–87CrossRef
7.
Fang G-D, Fine MJ, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM (1990) New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine (Baltimore) 69:307–316
8.
Fass RJ (1993) Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 32(Suppl A):17–27
9.
10.
Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275:134–141
11.
Garau J (2002) Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2:404–415CrossRef
12.
Garau J (2001) Clinical failures: the tip of the iceberg? Respir Med 95(Suppl A):S5–S11CrossRef
13.
File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A (1997) A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 41:1965–1972PubMed
14.
Forgarty C, Grossman C, Williams J, Haverstock D, Church D (1999) Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 16:748–763
15.
Ramirez J, Nguyen TH, Tellier G, Coppola G, Bettis R, Dolmann A, St Pierre C, Mayer H (1999) Once-daily 400 mg oral gatifloxacin (GAT) vs twice-daily 500 mg oral clarithromycin (CLA) in the treatment of community-acquired pneumonia. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. 2242
16.
File TM Jr, Schlemmer B, Garau J, Cupo M, Young C, and the 049 Clinical Study Group (2001) Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 48:67–74CrossRef
17.
Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN (2003) The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52:229–246CrossRef
18.
Yu VL, Vergis EN (1998) New macrolides or new quinolones as monotherapy for patients with community-acquired pneumonia. Our cup runneth over? Chest 113:1158–1159
19.
Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ (2002) A critical review of the fluoroquinolones. Drugs 62:13–59
20.
Periti P, Mazzei T, Mini E, Novelli A (1993) Adverse effects of macrolide antibacterials. Drug Saf 9:346–364
21.
Harrison BD, Farr BM, Connolly CK, MacFarlane J, Selkon JB, Bartlett CL (1987) The hospital management of community-acquired pneumonia. Recommendations of the British Thoracic Society. J R Coll Physicians Lond 21:267–269
22.
Niederman MS, Bass JBJ, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sorosi GA, Torres A, Yu VL (1993) Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. American Thoracic Society. Medical section of the American Lung Association. Am Rev Respir Dis 148:1418–1426PubMed
23.
Huchon G, Woodhead M, and the European Study on Community-Acquired Pneumonia Committee (1998) Guidelines for management of adult community-acquired lower respiratory tract pneumonia. Eur Respir J 11:986–991CrossRef
24.
Mandell LA, Marrie TJ, Grossman RF, Chow AT, Hyland RH, and the Canadian Community-Acquired Pneumonia Working Group (2000) Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31:383–421CrossRef
25.
MacFarlane J, Boswell T, Douglas G, Finch R, Holmes W, Honeybourne D, Lim WS, Marriott R, Nathwani D, Saul P, Woodhead M, Wyatt J (2001) BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56:iv1–iv64CrossRef
26.
Mandell LA, Bartlett JG, Dowell SF, File T, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433CrossRefPubMed
27.
Garau J (2001) Have guidelines had an impact on antimicrobial resistance? Semin Respir Infect 16:210–214CrossRef
28.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250CrossRefPubMed
29.
Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, Quinn TC, Hopkins, and the CAP Team (1998) Implications for macrolide treatment in community-acquired pneumonia. Chest 113:1201–1206
30.
Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT (2003) Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 23:1167–1174CrossRef
31.
File TM Jr, Tan JS (2003) International guidelines for the treatment of community-acquired pneumonia in adults. The role of macrolides. Drugs 63:181–205
32.
File TM, Tan JS, Plouffe JF (1998) The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 12:569–592PubMed
33.
Waterer GW, Baselski VS, Wunderink RG (2001) Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician’s viewpoint. Am J Med 110:41–48CrossRef
34.
Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, Low DE, Rubenstein E, Wise R (2002) Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49:31–40CrossRef
35.
Baquero F (1999) Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 11:35–43
36.
Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Eschaquen A, Gareen IF, Reiss PT, Maderios AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564CrossRefPubMed
37.
File T (2002) Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 34(Suppl 1):S17–S26CrossRef
38.
Miravitlles M, Murio C, Guerrero T, Gisbert R, and the DAFNE Study Group (2002) Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121:1449–1455CrossRef
39.
Fine MJ, Pratt HM, Obrosky S, Lave JR, McIntosh LJ, Singer DE, Coley CM, Kapoor WN (2000) Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 109:378–385CrossRef
40.
Yagupsky P, Porat N, Fraser D, Prajgrod F, Merires M, McGee L, Klugman K, Dagan R (1998) Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis 177:1003–1012
41.
Iannini PB, Tillotson GS (2000) Combating RTI: designing an antimicrobial to meet key criteria for success. Consultant 40(Suppl):S21–S28
42.
World Health Organization (2001) WHO global strategy for containment of antimicrobial resistance. Document no. WHO/CDS/CSR/DRS/2001.2. WHO, Geneva
43.
White AR, Kaye C, Poupard JA, Pypstra R, Woodnutt G, Wynne B (2004) Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 53(Suppl S1):i3–i20CrossRef
44.
Rolinson GN (1979) 6-APA and the development of the β-lactam antibiotics. J Antimicrob Chemother 5:7–14
45.
Sykes RB (2000) From moulds to drugs. Clin Microbiol Infect 6(Suppl 3):10–12
46.
Bryskier A (2000) Perfecting the ring and extending the antibacterial spectrum: “the multiple generations”. Clin Microbiol Infect 6(Suppl 3):13–21CrossRef
47.
Jacobs MR (2004) Building in efficacy: developing solutions to combat drug-resistant Streptococcus pneumoniae. Clin Microbiol Infect 10(Suppl 2):18–27CrossRef
48.
Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–12
49.
Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261–268CrossRefPubMed
50.
Woodnutt G, Berry V (1999) Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 43:29–34
51.
Drusano GL, Craig WA (1997) Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 9(Suppl 3):38–44
52.
Craig WA (2001) Re-evaluating current antibiotic therapy. Respir Med 95(Suppl A):S12–S19CrossRef
53.
Dagan R (2003) Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int J Infect Dis 7(Suppl 1):S21–S26CrossRef
54.
Schentag JJ (1990) Correlation of pharmacokinetic parameters of efficacy of antibiotics: relationship between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scan J Infect Dis 74(Suppl):218–234
55.
Todd PA, Benfield P (1990) Amoxicillin/clavulanate. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39:264–307
56.
Chulavatnatol S, Charles BG (1994) Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects. Br J Clin Pharmacol 38:274–277
57.
Pallares R, Fenoll A, Liñares J, and the Spanish Pneumococcal Infection Study Network (G03/103) (2003) The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 22:S15–S24CrossRef
58.
Ramgoolam A, Steele R (2002) Formulations of antibiotics for children in primary care. Pediatric Drugs 4:323–333
59.
Korppi M (2003) Community-acquired pneumonia in children. Issues in optimizing antibacterial treatment. Drugs 5:821–832
60.
Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR (1998) Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 17:865–871CrossRef
61.
Wubbel L, Muniz L, Ahmed A, Trujillo M, Carubelli C, McCoig C, Abramo T, Leinonen M, McCracken GH Jr (1999) Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 18:98–104CrossRef
62.
Bergan T (1984) Pharmacokinetics of the beta-lactam antibiotics. Scand J Infect Dis 42(Suppl):83–98
63.
File TM Jr, Garau J, Blasi F, Chidiac C, Klguman K, Lode H, Lonks JR, Mandell L, Ramirez J, Yu V (2004) Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 124:1888–1901CrossRef
64.
Garau J, Lonks JR, Gomez L, Xercavins M, Medeiros AA (2000) Failure of macrolide therapy in patients with bacteremia due to macrolide-resistant Streptococcus pneumoniae. In: Abstracts of the 5th International Conference on Macrolides, Azalides and Streptogramins. Abstract no. N709
65.
Kelley MA, Weber DJ, Gilligan P, Cohen MS (2000) Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 31:1008–1011CrossRef
66.
Fogarty C, Goldschmidt R, Bush K (2000) Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 31:613–615CrossRef
67.
Waterer GW, Wunderink RG, Jones CB (2000) Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 118:1839–1840CrossRef
68.
Delgine B, Turgeon PL, Fleury C, Lamothe F, Gaudreau C, Bourgault A, Vincelette J, Lette L (2001) Are macrolides still appropriate for empiric therapy of community-acquired pneumococcal pneumonia? In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. L-1849
69.
Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgensen JH, Le Magueres P, Krause KL (2002) Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 346:630–631CrossRef
70.
Butler JC, Lennox JL, McDougal LK, Sutcliffe JA, Tait-Kamradt A, Tenover FC (2003) Macrolide-resistant pneumococcal endocarditis and epidural abscess that developed during erythromycin therapy. Clin Infect Dis 36:e19–e25CrossRef
71.
van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J (2003) Breakthrough pneumococcal bacteremia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 51:691–696CrossRef
72.
Perez-Trallero E, Marimon JM, Iglasias L, Larruskain J (2003) Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 9:1159–1162
73.
Peric M, Bozdogan B, Jacobs MR, Appelbaum PC (2003) Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 47:1017–1022CrossRef
74.
Kuehnert MJ, Nolte FS, Perlino CA (1999) Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 131:312–313
75.
Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ (2001) Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 184:794–798CrossRef
76.
Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME (2001) Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 35:687–690CrossRef
77.
Piper J, Couch K, Tuttle D, Steele-Moore L (2001) Epidemiology and clinical outcomes of patients with levofloxacin-resistant pneumococcus. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. L-902
78.
Kays MB, Smith DW, Wack ME, Denys GA (2002) Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395–359CrossRefPubMed
79.
Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750CrossRefPubMed
80.
Anderson KB, Tan JS, File TMJ, DiPersio JR, Willey BM, Low DE (2003) Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 37:376–381CrossRefPubMed
81.
Chen DK, McGeer A, de Azavedo JC, Low DE (1999) Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341:233–239CrossRef
82.
Liñares J, de la Campa AG, Pallares R (1999) Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 341:1546–1547CrossRef
83.
Thornsberry C, Ogilvie PT, Holley HPJ, Sahm DF (1999) Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother 43:2612–2623
84.
Sahm D, Jones M, Hickey ML, Diakun D, Mani S, Thornsberry C (2000) Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe 1997–1998. J Antimicrob Chemother 45:457–466CrossRef
85.
World Health Organization (1999) Essential drugs and medicines policy. Alert no. 86. Trovafloxacin and alatrofloxacin: suspension & warnings: hepatotoxicity. http://​www.​who.​int/​medicines/​library/​qsm/​drugalert/​alert86.​htm.​ Cited 1 July 2004
86.
Buckingham SC, Brown SP, Joaquin VH (1998) Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 132:174–176
87.
Simmons WP (1999) Moraxella catarrhalis pneumonia and bacteremia in an otherwise healthy child. Clin Pediatr (Phila) 38:560–561
88.
Dowell SF, Smith T, Leversedge K, Snitzer J (1999) Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 29:462–463
89.
Sacho H, Klugman KP, Koornhof HJ, Ruff P (1987) Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus. J Infect 14:188–189
90.
Feldman C, Kallenbach JM, Miller SD, Thorburn JR, Koornhof HJ (1985) Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med 313:615–617
91.
Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid BF, Andremont A, Klugman K (2003) An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37:230–237CrossRef
92.
Andes D (2001) Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 14:165–172CrossRef
93.
Craig WA (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dose regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89–96CrossRef
94.
95.
McGee L, Goldsmith CE, Klugman K (2002) Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 49:173–176CrossRef
96.
Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC (2003) Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J Antimicrob Chemother 52:1018–1021CrossRef
97.
Friedland IR (1995) Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 14:885–890PubMed
98.
Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F (1995) Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333:474–480CrossRef
99.
Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, Mensa J (1999) Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 159:1835–1842
100.
Garau J, Aguilar L, Rodriguez-Creixems M, Dal-re R, Perez-Trallero E, Rodriguez M, Bouza E (1999) Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy. J Chemother 11:266–272
101.
Turret G, Blum S, Fazal B, Justman J, Telzak E (1999) Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 29:321–327
102.
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229PubMed
103.
Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF (2000) Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30:520–528CrossRef
104.
Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A (2001) Clinical outcomes of bacteremic pneumoccal pneumonia in the era of antibiotic resistance. Clin Infect Dis 33:797–805CrossRef
105.
Ailani RK, Alimchandani A, Hidalgo J, Ailani R, Buckley J, DiGiovine B (2002) Cephalosporin-resistant pneumococcal pneumonia: does it affect outcome? Respir Med 96:805–811CrossRef
106.
Plaut ME, Perlino CA (1978) Cefamandole vs. procaine penicillin for treatment of pneumonia due to Streptococcus pneumoniae: a random trial. J Infect Dis 137(Suppl):S133–S138
107.
Raff MJ, Rogers JH, Barnwell PA, Waterman NG (1978) Cefazolin in the treatment of pneumonia. Int J Clin Pharmacol Biopharm 16:78–82
108.
Bax RP, Dawson AF, Mullinger BM, Dash CH (1979) Cefuroxime in the treatment of lower respiratory tract infection. Curr Med Res Opin 5:772–778
109.
Nolen TM, Phillips HL, Hutchison J, Cocchetto DM (1988) Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic. Curr Ther Res 44:821–829
110.
Schleupner CJ, Anthony WC, Tan J, File TM, Lifland P, Craig WA, Vogelman B (1988) Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 148:343–348CrossRef
111.
Barradas P, Zamith M, Videira W, Cardosa T, Marques RA, Avila R (1989) Therapy of lower respiratory tract infections: a comparison of ceftriaxone and cefotaxime. Chemotherapy 35(Suppl 2):33–40
112.
Yangco BG, Lowe J, Nolen TM, Schleupner C, Tan JS, Anthony W (1990) A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults. Clin Ther 12:440–446
113.
Shalit I, Dagan R, Engelhard D, Ephros M, Cuningham K (1994) Cefuroxime efficacy in pneumonia; sequential short-course IV/oral suspension therapy. Isr J Med Sci 30:684–689
114.
Williams D, Perri M, Zervos MJ (1994) Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 13:293–298
115.
Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, and the Canadian Bronchitis Study Group (1995) Clarithromycin versus cefaclor in lower respiratory tract infections. Clin Invest Med 18:131–138
116.
Bohte R, van’t Wout JW, Lobatto S, Blusse van Oud Alblas A, Boekhout M, Nauta EH, Hermans J, van den Broek PJ (1995) Efficacy and safety of azithromycin versus benzyl penicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 14:182–187
117.
Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G (1995) Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 8:1999–2007CrossRef
118.
Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ (1996) Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 37:555–564
119.
Oh HML, Ng AWK, Lee SK (1996) Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J 37:255–257
120.
Amir J, Harel L, Eiditz-Markus T, Varsano I (1996) Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. Clin Pediatr (Phila) 35:629–633
121.
Camargos PA, Guimaraes MD, Ferreira CS (1997) Benzathine penicillin for unilateral lobar or segmental infiltrates presumptively caused by Streptococcus pneumoniae in children 2–12 years old. J Trop Pediatr 43:353–360CrossRef
122.
Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C (1997) Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 112:406–415
123.
Calver AD, Walsh NS, Quinn PS, Barab C, Lonergan V, Singh KP, Orzolek WS (1997) Dosing of amoxicillin/clavulanate given every 12 h is as effective as dosing every 8 h for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 24:570–574
124.
File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A (1997) A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 41:1955–1972
125.
Nogeova A, Galova K, Krizan L, Sufliarska S, Cizmarova E, Raskova J, Hrachova J, Kukova Z, Durcanska K, Krcmery VJ (1997) Ceftibuten vs. cefuroxime-axetil in initial therapy for community-acquired bronchopneumonia: randomized multicentric study in 140 children. Infect Dis Clin Pract 6:133–134
126.
Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E (1998) A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30:397–404CrossRefPubMed
127.
Tremolieres F, de Kock F, Pluck N, Daniel R (1998) Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 17:447–453CrossRef
128.
Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC, Sansores-Martinez RH, Hassan M, Beppo O, Wongsa A, Cukier A, Vargas F (1999) Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections. Int J Clin Pract 53:325–330
129.
Peterson J, and the Trovafloxacin Study Group (1999) Oral trovafloxacin vs oral cefuroxime ± erythromycin in community-acquired pneumonia. Drugs 58(Suppl 2):301–303
130.
Vergis EN, Indorf A, File TMJ, Phillips J, Bates J, Tan J, Sarosi GA, Grayston JT, Summersgill J, Yu VL (2000) Azithromycin vs cefuroxime plus erythromycin for empiric treatment of community-acquired pneumonia in hospitalized patients. A prospective, randomized, multicenter trial. Arch Intern Med 160:1294–1300
131.
Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R, Manresa F, Gudiol F (2001) Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microbiol Drug Res 7:85–96CrossRef
132.
Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, and the CAP5 Moxifloxacin Study Group (2001) Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119:185–195CrossRefPubMed
133.
van Zyl L, le Roux JG, LaFata JA, Volk RS, Paolo WA, Flamm R, Hom RC (2002) Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther 24:1840–1853CrossRef
134.
Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, and the 556 Clinical Study Group (2002) The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 20:119–129CrossRef
135.
Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A, and the 557 Clinical Study Group (2003) Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 52:826–836CrossRef
136.
File T, Lode H, Kurz H, Crann R (2003) Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). In: Abstracts of the 99th International Conference of the American Thoracic Society. Abstract no. B311
137.
Garau J (2004) Performance in practice: bacteriological efficacy in patients with drug-resistant Streptococcus pneumoniae. Clin Microbiol Infect 10(Suppl 2):28–35CrossRef
Metadata
Title
Role of beta-lactam agents in the treatment of community-acquired pneumonia
Author
J. Garau
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-1287-9

Other articles of this Issue 2/2005

European Journal of Clinical Microbiology & Infectious Diseases 2/2005 Go to the issue

Concise Article

Neisseria meningitidis C:2b:P1.2,5 with decreased susceptibility to penicillin isolated from a patient with meningitis and purpura fulminans

Brief Report

A reliable method to detect bacterial contamination of blood components using an automated blood culture system

Article

Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis

Concise Article

Three cases of destructive native valve endocarditis caused by Staphylococcus lugdunensis

Concise Article

Long-term survival and interruption of HAART in HIV-related pulmonary hypertension

Article

Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997–1998
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits